Harrow (HROW) Net Cash Flow Growth (3y) (2013 - 2026)
Harrow (HROW) Net Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | -28.90% |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | -5.41% |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | 19.55% |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | 95.24% |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | -106.21% |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | 4.40% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 17.73% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Harrow | 1.56 Bn | 1.47 Bn | 50.36 Mn | -71.76% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -71.76% |
| Mar 31, 2026 | 31.65% |
| Dec 31, 2025 | -26.55% |
| Sep 30, 2025 | 154.17% |
| Jun 30, 2025 | -71.74% |
| Mar 31, 2025 | 349.70% |
| Dec 31, 2024 | -17.35% |
| Sep 30, 2024 | 28.24% |
| Jun 30, 2024 | -66.79% |
| Mar 31, 2024 | -65.32% |
| Dec 31, 2023 | 99.53% |
| Sep 30, 2023 | 197.66% |
| Jun 30, 2023 | 444.42% |
| Mar 31, 2023 | -353.65% |
| Dec 31, 2022 | 238.92% |
| Sep 30, 2022 | -38.06% |
| Jun 30, 2022 | 300.75% |
| Mar 31, 2022 | 56.01% |
| Dec 31, 2021 | -217.47% |
| Sep 30, 2021 | -107.94% |